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AbstrAct
Treatment with a single drug targeting a specific 
receptor is no longer considered optimal in the 
treatment and management of complex diseases 
such as HIV/AIDS, diabetes, and cardiovascular 
disease. Potential health benefits may arise from 
the use of affordable, multiple-target, fixed-
ratio drug combinations, which concomitantly 
reduce multiple risk factors without increasing 
the risk of adverse effects. Main goals for 
development of fixed-dose drug combinations 
may largely be based on the following concepts: 
treatment of two closely related diseases (e.g., 
hyperlipidemia and hypertension), patients 
insufficiently controlled by optimally dosed 
individual monotherapies, and substitution of 
fixed-dose combination versus free combination. 
Success in creating and developing the best-
in-class commercial combination products 
requires a multifaceted approach including the 
following: 1) treatment paradigms in therapeutic 
area; 2) patient compliance and impact of 
personalized medicine; 3) shifts in market and 
cost drivers; 4) preclinical and pharmaceutical 
development and manufacturing; 5) competitive 
intellectual property landscape; and 6) clinical 
development and regulatory filing strategy. 
Assessment of risks and probability of success 
of specific drug combinations and drug delivery 
technologies are needed in order to arrive at the 
proper recommendation and risk mitigation 
plans. Personalization of combination therapy 
is rationalized on the theoretical premise of 
division of clinical responders from partial or 
nonresponders to drugs in diseases for which 
known biomarkers exists. Combination drug 
therapies with individualized optimization 
are likely to become a major future focus. A 
comprehensive review of industrial practice 
and literature is presented with the goal of 
developing a best practices roadmap in the 
feasibility assessment of drug combination 
therapies.
Enhanced content for Combination 
Products in Therapy articles is 
available on the journal web site: 
www.combitherapy-open.com
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INtrODUctION
Combination products range from drug-drug 
combinations [1, 2], drug-device combinations 
such as drug-eluting stents for coronary 
blockages, and drug-biological product such 
as monoclonal antibodies combined with a 
chemotherapy agent for cancer treatment [3–5]. 
Treatment with a single drug targeting a specific 
receptor is no longer considered optimal in the 
treatment and management of complex diseases 
such as HIV/AIDS, diabetes, and cardiovascular 
disease. Potential health benefits may arise from 
the use of affordable, multiple-target, fixed-ratio 
drug combinations, which concomitantly reduce 
multiple risk factors without increasing the risk 
of adverse effects. In the case of an infectious 
disease such as HIV, the potential benefits of 
fixed-dose combination (FDC) therapy include 
the prevention of viral drug resistance by 
decreasing levels of viral replication and raising 
the genetic barrier to resistance development.
Increased emphasis on the development 
and marketing of FDC drugs is an essential 
component of lifecycle management of both 
established marketed drugs and new chemical 
entities for which single-agent and combination 
studies could advantageously be integrated 
during early stages of clinical development. 
Literature analysis of notable FDC candidates in 
clinical development have largely pointed out 
the need to fill gaps in product pipelines and 
to maximize commercial returns of established 
products owing to patent expiration pressures 
faced by many pharmaceutical companies.
However, the ultimate success in creating 
and developing the best-in-class commercial 
combination products may be achieved by 
addressing unmet patient needs. This requires 
a multifaceted approach to the assessment of 
risks and opportunities in virtually all aspects 
of the drug development process including the 
following: 1) treatment paradigms in therapeutic 
area; 2) patient compliance and impact of 
personalized medicine; 3) shifts in market and 
cost drivers; 4) preclinical and pharmaceutical 
development and manufacturing; 5) competitive 
intellectual property (IP) landscape; and 6) 
clinical development and regulatory filing 
strategy.
In this article, a comprehensive review of 
industrial practice and supporting literature is 
presented with the goal of developing a best 
practices roadmap in the feasibility assessment 
of drug combination therapies.
MEtHODs
The literature search was designed to 
identify articles and other documents on the 
development of drug-drug combinations in a 
pharmaceutical industrial setting as described 
in the individual sections below. Searches 
of literature databases and online sources of 
regulatory information and industrial news, 
analysis, and perspective were carried out in 
the context of providing real-life examples 
from the literature. Multiple information 
resources and indexes were searched using 
general and specialized search engines, 
including Google Scholar and Science.gov. 
Relevant papers on the topic were categorized, 
and by examining their bibliographies, 
additional articles were identified. Applicable 
journals were reviewed for germane articles 
on the topic. A commercial reference 
management software package (Endnote) was 
used to search Internet databases (PubMed) 
and manage references.
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trEAtMENt PArADIGMs IN 
tHErAPEUtIc ArEA
Justification for Multiple Target 
Combination Therapy
Merit for combining various active components 
in a single-dosage unit is based on therapeutic 
treatment principles and medical practice. 
Synergism from combining drugs with different 
modes of action to treat a disease or diseases 
may potentially lead to better therapeutic 
efficacy, improved tolerability by lowering the 
dose, or by developing new presentations and 
regimens (e.g., once daily dosing). For example, 
there is prevalence of overlapping cardiovascular 
risk factors in a vast proportion of patients with 
coronary disease and type 2 diabetes. Multimodal 
combination drugs target a number of risk 
factors in a single tablet. Diabetes often coexists 
with dyslipidemia and dyslipidemic patients also 
suffer from hypertension. Antiretroviral drugs 
are combined to improve the drug-resistance 
profile by raising the genetic barrier to resistance 
development and by preventing development 
of drug resistance through decreasing levels of 
viral replication, thereby transforming HIV from 
a terminal illness to a chronically manageable 
disease.
The current US Food and Drug Administration 
(FDA) policy for FDC was established in 1971. 
The policy states that “two or more drugs may 
be combined in a single dosage form when each 
component makes a contribution to the claimed 
effects and the dosage of each component 
(amount, frequency, duration) is such that the 
combination is safe and effective for a significant 
patient population requiring such concurrent 
therapy as defined in the labeling for the drug.” 
Essentially these combination modalities fall 
into three categories concurrent with FDA and 
European Committee for Proprietary Medicinal 
Product guidance’s on fixed combination 
medicinal products [6, 7].
First-Tier Category: Improvement of Activity 
and/or Tolerability
Drugs in the combination product have different 
mechanisms of action often with a single 
aim such that the therapeutic effect is either 
improved or broadened with a side-effect profile 
similar to that of respective monotherapies given 
at the same or higher dose. For example a recent 
study found that the triple-drug combination of 
olmesartan/amlodipine/hydrochlorothiazide for 
the treatment of hypertension was very effective, 
safe, and well tolerated by patients [8]. Other 
recent clinical reviews of new drug medications 
include effectiveness and safety of two drug 
combinations for type 2 diabetes [9] and for 
dyslipidemia and obesity treatment in metabolic 
syndrome [10]. Alternatively, tolerance of a low-
dose combination of drugs is improved with 
similar therapeutic effectiveness over respective 
higher dose monotherapies [11].
Examples of well-established FDC that are 
approved or in late-stage development, as well 
as new single agent monotherapies, and FDC in 
current pipeline for prominent therapeutic areas 
are provided in Tables 1–4. The information 
includes the potency of each therapeutic agent, 
mode of action, current phase, trade name, 
and companies for therapies in cardiovascular, 
HIV/AIDS, hepatitis diseases, and diabetes 
(Tables 1–4, respectively).
Second-Tier Category: Improvement in 
Symptomatic and Pharmacokinetic Profile
These combinations may contain at least one 
component not previously approved for an 
indication. The intensity and duration of action 
of monotherapy is increased by combining 
with a second component that reduces the 
metabolic inactivation or elimination of the 
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other agent or agents, such as the addition of 
the booster agents, ritonavir and cobicistat 
(GS 9350), to enhance the antiretroviral (ARV) 
effect of protease and integrase inhibitors [12]. 
Alternatively, a component in the FDC acts by 
diminishing the dose-related side effects of the 
other agent such as the addition of laropiprant 
to a FDC of niacin and statin to counteract the 
skin-flushing effect of high-dose niacin.
Third-Tier Category: Simplification of Dosage 
Regimen
In general, regulatory guidelines have demerited 
FDC products that promote convenience claims 
without providing additional health benefits. 
However, improving compliance and adherence 
to therapy brought about by reducing the pill 
burden or simplifying the dosing regimen, such 
as once daily, may be sufficient proof to provide 
regulatory flexibility. The issue of adherence is 
particularly important in the areas of infectious 
diseases and diabetes where inadequate or 
inconsistent adherence to multiple therapy and 
dosing regimen may lead to the development of 
viral resistance and inadequate glycemic control, 
respectively [13, 14].
Inherent Risks of Combination Products
Selection of the Most Appropriate Therapeutic 
Agents
Arguably the foremost risk factor is in the 
selection of the most appropriate therapeutic 
agents intended for development as a 
combination product. In other words, does 
the proposed combination of drugs and doses 
represent the most clinically appropriate choice 
of drugs based on available efficacy, safety, 
and cost data? If this first condition is not 
satisfactorily vetted, it is possible that a less 
optimal FDC is chosen because of its availability 
and the perceived improved adherence rather 
than its demonstrated clinical benefits. 
A less optimal FDC may also occur when 
pharmaceutical companies develop combination 
drugs exclusively from their own portfolio 
whereas more viable alternative drugs from other 
companies are overlooked. Recent examples are 
montelukast/loratadine FDC for allergic rhinitis, 
and niacin/laropiprant for hypercholesteremia.
Multiple Drug–Drug Interactions
The administration of FDC raises the risk 
of multiple drug-drug interactions and 
unexpected adverse events. Pharmacokinetic 
and pharmacodynamic data are needed to 
assess adverse effects of drug-drug interactions 
particularly in high-risk subgroups, such as 
the elderly and patients with diabetes and/or 
renal disease [15]. Only for established drugs 
that are often prescribed concomitantly, well-
documented bibliographic data may provide a 
rationale to minimize the number of new studies 
needed to establish safety and efficacy of the 
proposed combination.
Loss of Therapeutic Flexibility
Another risk is loss of therapeutic flexibility 
for titration. Combining agents with different 
therapeutic targets, such as hyperlipidemia 
and hypertension, require dose titration of 
each drug component. Developing too many 
dose combinations could defeat the object of 
developing a simplified combination therapy. 
For example, Pfizer (NY, USA) developed
11 different dosing combinations of Caduet® 
(amlodipine besylate/atorvastatin calcium) to 
accommodate this need [16].
Life Cycle Management (LCM) Development 
Strategy
If LCM strategies are left late in the development 
cycle until close to patent expiration, there is a 
business risk that the developed FDC may quickly 
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be superseded by other drug combinations over 
time in a competitive landscape. For example, 
ARV regimens of two drug combinations were 
superseded by three drug combinations. “Quad 
pill” was developed by Gilead Sciences (Foster 
City, CA, USA) that combines four distinct ARV 
components in a single dosage (Table 2). Also, a 
potential novel combination with new chemical 
entities requires early integration of complex 
preclinical and clinical development programs.
Patient Acceptance Criteria
For oral medications, there is a risk that the 
combination tablet may be too big for some 
patients to swallow, particularly if more than 
one large unit is to be taken together at once. 
Such risks can be mitigated to some extent by 
dosage formulation design and manufacturing 
technology to minimize physical size and 
dimensions and by conducting preliminary 
market research based on sight samples of the 
FDC and its comparison to other large-size 
medications on the market.
Patient Compliance and Impact of 
Personalized Medicine
From the patient’s perspective, polypharmacy 
and the complexity of the medication regimen 
are important factors for noncompliance [17]. 
The incentive for simplification of therapy 
is to improve compliance and adherence 
to medication in order to improve health 
outcomes [18]. The relationship between 
adherence to ARV combination regimen and 
development of drug-resistant viral mutations 
and replication was reviewed by Bangsberg 
et al. [19].
The National Council on Patient Information 
and Education has estimated that because of 
poor adherence between 30–50% of prescriptions 
fail to produce the desired therapeutic results in 
patients with chronic medical conditions [20]. 
Several studies in compliance literature have 
provided data to support this theory [21, 22]. 
Bangalore et al. [23] conducted a review of 
randomized, controlled trials and a retrospective 
analysis of medication compliance for nine 
studies that compared FDC with free-drug 
regimens of the same medication. The chronic 
conditions were hypertension in four studies, 
diabetes in two studies, tuberculosis in two 
studies, and HIV infection in one study. A total of 
11,925 patients on FDC were compared against 
8,317 patients on monotherapy regimens. The 
meta-analysis showed that FDC resulted in a 
24–26% greater patient compliance across all 
groups.
Impact of Personal Medicine
An ultimate paradigm is to personalize 
treatment to individual circumstances. Each 
patient has unique characteristics, such as 
weight, age, pharmacogenetics, and co-existing 
illnesses, and genetic polymorphism affecting 
drug metabolism, transport, and effect (both 
efficacious and adverse). This may argue for 
close monitoring, and optimization of dose 
and frequency of individual drugs as opposed 
to administration of a FDC tablet. However, 
personalization of combination therapy is 
rationalized on theoretical premise of division of 
clinical responders from partial or nonresponders 
to drugs in diseases for which known biomarkers 
exists [24, 25].
Pharmacogenomics seeks to identify and 
validate molecular diagnostic assays/tools for 
defining pathogenesis and stratifying patient 
population into treatment responders and 
nonresponders. Clinical diseases in which 
personalized medicine is taking an increasing 
prominent role includes cancer treatment, 
diabetes, cardiology, and neurology [26].
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Although the impact of personalized 
medicine on practical strategies used to design 
combination products remains to be seen, initial 
emphasis may focus on anticancer drugs and 
the development of concomitant companion 
diagnostics. In this respect, FDA draft guidance 
on in-vitro companion diagnostic devices points 
to several key features [27]. First, it defines 
in-vitro companion diagnostics (IVDs) as devices 
that provide essential information for the safe 
and effective use of corresponding therapeutic 
products, by identifying individuals most likely 
to benefit or suffer adverse reactions from 
treatment. Second, it states that FDA will review 
targeted drugs for approval only in the context 
of their corresponding IVDs. Third, it aims to 
clarify drug labeling by identifying what types 
of FDA-approved IVDs are appropriate for use in 
selecting patients and their monitoring.
Recent such examples include: 1) approval 
of vemurafenib and multiple polymerase chain 
reaction (PCR)-based diagnostic for BRAF V600 
E gene for advanced melanoma harboring the 
mutation, and 2) crizotinib for non-small cell 
lung cancer in patients with tumors containing 
anaplastic lymphoma kinase (ALK) gene with a 
fluorescent in situ hybridization (FISH) test for 
detecting rearrangements of the ALK gene [28].
The realization of these expectations requires 
medications with a biomarker test, and large-
scale patient data on associations between 
genotypes and drug-response phenotypes from 
clinical trials [29–31]. Researchers have called for 
forming knowledge management infrastructure 
systems devoted to archiving and analyzing 
pharmacogenetics data from many thousands 
of individuals toward tools for personalized 
medicine.
A bioinformatics research pilot study in 
Huntington’s disease was established at GE 
Global Research Center to develop predictive 
models that combined medical informatics; 
i.e., methods to identify statistical correlations 
within clinical data with bioinformatics, which 
provides knowledge of polymorphism in genes 
that encode proteins that are the target of the 
proposed drug [32]. The Marshfield Clinic 
Personalized Medicine Research Project (PMRP) 
represents one of the largest population-
based DNA biobanks in the United States. 
Wilke et al. [33], as part of an effort to begin 
phenotyping common diseases such as diabetes 
within the PMRP database, constructed a 
diabetes case-finding risk algorithm that utilized 
diabetes diagnostic codes in combination with 
clinical laboratory data and medication history. 
This algorithm yielded an estimated prevalence 
of 24.2% for diabetes mellitus in adult subjects 
50 years or older. The implication is to identify 
individuals for targeted drug therapy either 
from less effective therapies or by identifying 
less symptomatic individuals who might benefit 
from prophylactic treatment (no antidiabetic 
drugs are presently licensed for use in prediabetic 
individuals).
As previously discussed, drug and 
biomarker diagnostic combinations (also 
termed theranostics) have been categorized 
on the basis of their use for clinical response/
efficacy by differentiating potential responders 
from nonresponders, drug susceptibility, and 
resistance, and dose selection or adjustment 
to optimize drug efficacy and safety. The FDA 
calls for two types of testing: 1) required tests 
before prescribing specific drugs that are useful 
in identifying potential responders in whom 
drugs are shown to have an enhanced efficacy, 
and 2) recommended tests that assist with 
dose selection/adjustment to primarily prevent 
a drug’s severe adverse effects [34]. Further 
examples of the tests that are in current use are 
provided below:
1) Monogram Bioscience’s Trofile Assay for 
evaluating a patient’s antibody response to 
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envelope proteins of a virus was developed 
as a means to identify responders to 
maraviroc a C-C chemokine receptor type 5 
(CCR5) coreceptor antagonist compound for 
treatment of HIV [35, 36].
2) Determination of individual genetic 
characteristics of the tumor allows for 
possible tailoring of cancer treatment. Gene 
expression profiling studies have provided a 
molecular classification of breast cancer into 
clinically relevant subtypes for predicting the 
benefits of chemotherapy in newly diagnosed 
breast cancer patients. The commercially 
available Genomic Health’s Oncotype DX 21 
gene expression assay was shown to predict 
endocrine therapy response and recurrence 
out to 10 years in patients with estrogen 
receptor-positive, and lymph node-negative 
breast cancer. The clinical trial assigning 
individualized options for treatment was a 
large, multicenter, randomized trial (TAILORx) 
that used this genomic test [37–40]. More 
recently this was expanded to the use of a 
70-gene expression pattern predictor as a 
prognostic factor in breast cancer recurrence 
and patient stratification to low and high-risk 
groups [41].
3) A strong association was found between 
genetic polymorphism in the recently 
identified vitamin K epoxide reductase 
complex 1 (VKORC1) gene and inter-
individual variability in the adverse 
reactions to anticoagulant effect of warfarin. 
Genotyping test has made it possible to 
identify the variants in gene encoding 
(VKORC1 haplotypes) responsible, in part, for 
coumarin dose-adjustment requirements [42].
4) Niemann-Pick C1-like 1 (NPC1L1) gene 
encodes a intestinal sterol transporter, which 
is the likely target for ezetimibe, a cholesterol 
uptake inhibitor. DNA sequence variation in 
the NPC1L1 gene (several single nucleotide 
polymorphisms [SNP]) was associated with 
the improved low-density lipoprotein (LDL) 
lowering clinical response to treatment 
with ezetimibe. The association between 
changes in plasma sitosterol levels (a direct 
marker of cholesterol absorption) and SNP 
haplotypes were carried out in Caucasians 
in the ezetimibe add-on to statin for 
effectiveness (EASE) trial and vytorin versus 
atorvastatin (VYVA) trial, and in the two 
trials combined [43, 44].
5) DNA variation in organic cation transporter 1 
(OCT1) absorption, distribution, metabolism, 
and elimination (ADME) gene affects 
response to metformin, which is widely used 
as the first-line drug in treatment of type 2 
diabetes mellitus [45].
6) Other examples of genetic marker tests that are 
used to identify ethnic and racial differences 
in clinical response include the following 
cases: systemic administration of trastuzumab 
an anti-HER2 antibody in patients with the 
HER-2/neu (encodes a epidermal growth factor 
receptor protein) overexpressing breast cancer 
tumors [46]; a prognostic biomarker test used 
to detect polymorphism amongst patients 
with genotype 1 hepatitis C infection (a 
single allele change in a tiny segment of DNA 
code near the Interleukin-28B gene) guides 
treatment decisions to standard hepatitis C 
regimen (i.e., a combination of pegintron 
and the antiviral ribavirin). An application to 
use a genetic marker test to screen patients 
that might develop liver damage from taking 
lumiracoxib was recently resubmitted to FDA 
by Novartis AG.
Desp i te  numerous  sc ient i f i c  and 
implementation challenges for translating the 
concept of personalized medicine into clinical 
practice, progress is being made in providing 
structure for achieving consensus on public 
policy positions among stakeholders [47, 48].
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MArKEt sHIFts AND DrIVErs
It is well recognized that the overall costs for 
development of new chemical entities have 
continued to rise. Estimates of actual costs vary 
but that on average it represents $750 million 
to $1.1 billion research and development 
expenditure by the pharmaceutical industry. 
At the same time, loss of molecules and 
revenue due to patent expiration is outpacing 
the introduction of new ones to the market. 
Pharmaceutical companies are seeking different 
ways of revenue generation to offset this 
imbalance. LCM is seen as an essential strategy 
of drug franchise development, product 
revitalization, and maintenance or increase in 
market share. Generally, new combinations of 
established drugs carry low risk due to lower 
development costs (i.e., $10–50 million) and 
less burdensome regulatory path to approval 
since in many cases safety and efficacy of each 
individual marketed drug has been established. 
These combinations, if truly shown to satisfy 
an unmet need, create and extend value 
because of speed to market and generation of 
new patents that may protect from generic 
competition.
Cost-effectiveness of FDC in the outpatient 
setting is seen in terms of avoidance of 
medication errors (missed or omitted doses), 
improving adherence, and efficacy. Newman 
et al. applied decision modeling to analyze 
the cost-effectiveness of four FDCs for primary 
cardiovascular disease prevention in men 
which found FDCs to be cost-effective for men 
older than 55 years [49]. Securing favorable 
pharmacoeconomic coverage for FDC can 
be very challenging in today’s drug benefit 
and coverage trends but this may depend 
on therapeutic area, availability of generic 
versions of single agents, pricing, and other 
factors.
KEY PHArMAcEUtIcAL 
FOrMULAtION AND 
MANUFActUrING cHALLENGEs
Formulation development and manufacturing 
of multi-active component dosage forms 
present many unique challenges. These 
challenges may arise due to following scenarios: 
1) physicochemical incompatibility of the active 
pharmaceutical ingredients (APIs) with each other 
and with the common excipients used in the FDC 
formulation; 2) changes in the rate and extent of 
in-vitro dissolution and in-vivo bioavailability of 
APIs from FDC as compared to that observed for 
the single component formulations of individual 
APIs; 3) undesirable mechanical powder flow 
and compression characteristics of the multi-
active granulation/powder blend; and 4) increase 
in dosage bulk volume due to additional drug 
loading particularly for high-dose combinations.
For these reasons, a conventional tablet 
or capsule dosage form may rarely suffice to 
meet the various stability, bioequivalency, 
and commercial manufacturing requirements. 
Combinat ion  o f  API s  c la s s i f i ed  a s 
Biopharmaceutics Classification System (BCS) 
Class II and IV are particularly challenging 
and require specialized solubility enhanced 
formulations and amorphous conversion 
processing technologies that are capable of 
providing stable, bioavailable, and scalable 
formulation to accommodate the range of drug 
loading and potencies of each API. There could 
be also requirements for individual modification 
of drug release and pharmacokinetic profiles 
such that a combination of both immediate 
and extended drug release formulations may be 
needed for the combination dosage form.
If an API is initially formulated as a liquid 
or semi-solid encapsulated composition, its 
reformulation into a biocomparable solid state 
formulation could be a prerequisite in order to 
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make the combination with other drugs viable. 
A comparative in-vivo bioavailability study of 
liquid versus solid reformulation having a similar 
food effect can be used to determine if a modest 
upward potency adjustment can be supported 
by prior preclinical toxicological safety data 
to achieve a bioequivalent pharmacokinetic 
profile for the reformulated product. For BCS 
Class II and IV compounds, this may involve 
use of complex solid solubilization co-processing 
techniques such nanomilling, amorphous API 
solubilized polymeric dispersions, and surfactant 
co-granulation technologies.
Multilayer tablet technology is particularly 
useful for formulating FDC. It allows for 
compression of separate drug layers, thus 
minimizing physicochemical incompatibility 
and stability problems that may arise from the 
intimate contact of individual drug compositions. 
Atripla® (Gilead Sciences, Foster City, CA, USA) 
comprises of a dry granulation layer of tenofovir 
disoproxil fumarate and emtricitabine and a 
wet surfactant co-granulation layer of efavirenz 
[50]. Bilayer tablet technology also provides 
flexibility in combining formulations with 
sustained-release and immediate-release layers 
in the same dosage unit. This was utilized in 
developing combinations of extended release 
niacin (controlled-release layer) and immediate-
release layer of laropiprant with simvastatin 
or atorvastatin (Tredaptive in European Union 
[EU]). It is noted that physical and mechanical 
aspects of bilayer tablet compression is more 
complex than conventional single layer tablet 
compression. Challenges encountered are 
due to weight control of the thinner drug 
layer compression fill weight, and interfacial 
delamination. The latter may occur as a result 
of inadequate interfacial bonding strength 
immediately following ejection or upon further 
processing stress and attrition such as in pan 
film coating operation. Delamination may also 
occur due to differential expansion of the layers 
upon exposure to elevated humidity conditions 
upon storage and stability testing.
A strategy to reduce dosage size and enhance 
swallow ability is to apply precision film coating 
to deposit API as a polymer film layer (rather 
than a separate granulation layer) over a separate 
drug containing tablet core [51]. The drug core 
could be an extended release matrix core, a 
conventional tablet core, or a bilayer tablet. 
These formulation designs provide flexibility for 
various scenarios of combining multiple APIs, 
dosing combinations and drug release rates.
FDC development strategies for new 
chemical entities (NCEs) are increasingly being 
incorporated early during the compound 
development program, so that formulation 
design activities and manufacturing process 
development for both monotherapy and 
combination are performed in parallel. This 
strategy aims to avoid formulation switching and 
bioavailability issues from occurring late in the 
development program and commercial stages. 
However, in many cases FDC development takes 
place after initial approval of monotherapy is 
obtained. Therefore, existing knowledge of APIs 
preformulation and dosage form formulation 
and stability mechanisms can be heavily 
leveraged in experimental design to streamline 
and fast track FDC development and regulatory 
filing as much as possible.
A further strategy to minimize formulation 
development particularly when drug potencies 
are low is to incorporate them in a multi-
phase capsule technology, which involves 
co-encapsulation of existing tablet/powder 
blend/multiparticulates components in 
potentially sealed compartments. For example, 
Lotrel® (Novartis, East Hanover, NJ, USA) is 
marketed as a hard gelatin co-encapsulation of 
benazepril hydrochloride film-coated tablet and 
amlodipine besylate granulation powder blend.
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FDC Formulation, Manufacturing, and 
Regulatory Development Roadmap
There are common strategies and approaches 
that could be taken to successfully develop and 
market FDC products. The initial project scope 
and gap analysis activities could be initiated by 
a review of internal therapeutic area portfolio 
and by identifying unmet patient needs, new 
data or indication arising from clinical research 
and/or clinical practice setting as well as market 
and brand opportunities. Following gap analysis, 
the next steps are idea generation, prioritization, 
and a preliminary review of related API and 
formulation competitive IP landscape that may 
depend on combining approved drugs or NCEs. 
Assessment of risks and probability of success of 
specific drug combinations and drug delivery 
technologies are needed in order to arrive at 
proper recommendation and risk-mitigation 
plan.
These multidisciplinary plans are used 
to obtain initial organizational go/no-go 
decision to allow for allocation of resource 
funding pending more detailed technical and 
manufacturing reviews. This could be achieved 
by conducting a paper feasibility exercise 
focusing on technical API, formulation and 
process design aspects as well as regulatory and 
manufacturing challenges and opportunities 
for resolution. The paper feasibility assessment 
may contain several sections from information 
collected or generated during the prior project 
scoping and idea generation stages:1) target 
product profile; 2) API sourcing; 3) preclinical 
safety pharmacology considerations; 4) FDC 
formulation and process design; 5) IP issues; and 
6) regulatory filing strategy.
Target Product Profile
Target product profile comprises the first step in 
broadly defining objectives and requirements for 
meeting product target profile in terms of goals 
set for disease indication, clinical efficacy, safety, 
potency, route and frequency of administration, 
bioequivalencey criteria, and shelf-life stability. 
These objectives are aligned with organization of 
sections in the product’s label.
Target product quality profile (TPQP) aims 
to predefine chemistry, manufacturing and 
controls (CMC) requirements and performance 
criteria for product critical quality attributes 
(CQA) that focuses on guiding formulation, and 
manufacturing process development efforts. 
TPQP can be inclusive of predefining drug 
substance physical form, its biopharmaceutical 
properties, as well as dosage form characteristics, 
such as assay, content uniformity limits, 
compression properties, microbial limits, and 
impurity/degradant projected specification 
limits. In addition, dosage form performance 
criteria such as in vitro-dissolution profile, 
in-vivo bioavailability profile, stability, and 
package requirements are included [52]. These 
critical quality product attributes are refined and 
revised based on new data that are generated 
during the later experimental and development 
stages.
API Sourcing
In some situations a FDC product may involve 
combining an externally sourced API with 
therapeutic agent/s from innovator’s own 
internal development portfolio (whether 
marketed or an NCE). Externally sourced 
API often presents challenges in terms of its 
procurement. Such issues and risk-mitigation 
plans can often be considered in advance 
during the feasibility assessment stage and 
may include the following areas: 1) API 
vendor selection, vendor suitability, and 
status of prior quality assurance assessment 
if any, and procurement lead times and cost 
factors; 2) availability of drug master files for 
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investigational new drug regulatory filing in 
US, as well as early identification of IP factors 
that may require sourcing from overseas API 
vendors; 3) availability of Good Manufacturing 
Practice (GMP) quality and non-GMP material 
meeting standard pharmacopeia specifications 
as needed (US Pharmacopeia [USP], EU, Japanese 
Pharmacopeia [JP]) for conducting initial 
feasibility and stability studies; 4) applicability 
of drug importation requirements, such as 
securing in advance, investigational new drug 
application approval from regulatory authority 
for importation of GMP-quality material for 
human studies.
FDC Formulation and Process Design
Design of multi-active combination products 
requires knowledge of each individual API 
physicochemical and biopharmaceutical 
properties as well as sources and mechanism/s 
of chemical degradation and physical instability. 
API physicochemical profiling data are used 
to predict associated developability risks, 
and formulation complexity factors. For BCS 
Class II and IV compounds, initial selection of 
preferred solubilization enhancing technologies 
and inclusion of functional excipients depend 
on API physico-chemical and gastrointestinal 
(GI) physiological factors [53]. Traditional 
high-throughput robotic salt, and polymorph 
screens are supplemented by solubility screens 
of lead forms in various pH media, surfactant 
and vehicles that are intended to inform on 
solubility and dissolution of API (and its salt) 
forms as well as API-excipient blends under 
gastrointestinal relevant conditions [54–56]. The 
outcome is lead formulations that can achieve 
dissolution and supersaturation.
Selection of appropriate API phase, salt form 
and physical state together with API solubility 
data in physiologically relevant pH media 
(encountered in fasted stomach and proximal 
intestine), as well as estimated clinical dose 
solubility ratio, and intrinsic permeability can 
be used to forecast whether the oral absorption 
process is predominately limited by apparent 
solubility or by dissolution rate. Such predictions 
are increasingly made using physiologically-
based drug absorption modeling (PBPK), which 
represents the compartmental absorption 
and transit model (ACAT) implemented in 
the commercially available software such as 
GastroPlus, (Simulations Plus, Lancaster, CA, 
USA), and PK-Sim (Bayer Technology Services 
GmbH, Leverkusen, Germany) [57, 58].
Computational absorption simulations 
particularly when coupled with input parameter 
sensitivity analysis that for example simulates 
exposure for a range of doses and particle sizes 
may point to viable formulation options that are 
intended to improve oral bioavailability [59, 60]. 
These may include effect of salt formation, 
particle size reduction, amorphous and lipid 
formulations. In addition, in silico methods 
may be used to aid initial selection of suitable 
excipients, such as polymer and surfactants 
for drug solubilization. The latter includes 
molecular dynamics simulations capable 
of generating solubility and Flory-Huggins 
interaction parameters values as a means of 
predicting drug miscibility in drug-polymer 
binary mixtures. For solute-solvent pairs, it 
has been reported that values for difference in 
solubility parameters of less than 7.5 (J/cm3)1/2 
indicate good solubility of solute in the solvent. 
Furthermore, thermodynamic predictions can 
provide energetically favorable ranges of API/
polymer drug loading levels that result in either 
stable solid solution (up to about 10% drug 
loading) or metastable supersaturated solid 
solutions (up to approximately 40% DL) [61, 62].
Formulation design requires understanding 
of the API phase properties and its solubility/
miscibility in excipients coupled with the 
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application of appropriate pharmaceutical 
process ing technologies  designed to 
enhance apparent solubility (i.e., maintain a 
supersaturated state) and stabilize API solid-state 
transitions.
In-vitro dissolution of weak bases and 
their salts in simulated gastric and intestine 
fluid media (FaSSIF and FeSSIF containing bile 
salts) [63] is particularly relevant to indicate how 
dissolution of drug dose in luminal fluid volume 
is effected by solubility and supersaturation/
precipitation behavior of the free base in 
the GI pH range covering pre/postprandial 
conditions [64, 65]. For example, initial 
incomplete dissolution of very low soluble weak 
bases (and their salts) in acidic environment 
of fasting stomach may lead to rapid 
supersaturation and precipitation of the free base 
not likely to be dissolved/absorbed in the upper 
small intestine. Also, poorly soluble weak bases 
typically show higher rate and extent of in-vitro 
dissolution in FeSSIF media (as compared to 
FaSSIF media) indicating the solubilizing effect 
of bile salts/lecithin present in such media and 
hence forecast presence of significant food 
effect on their oral bioavailability profile. On 
the other hand, sparingly soluble weakly acidic 
molecules that have high permeability are 
well absorbed at the intestinal absorption site 
provided its relevant pKa (carboxylic acids 4–6) 
lies within a range to permit ionization of 
the unionized molecule [66]. Several broad 
categories of excipient that are commonly 
utilized in various solubilization technologies, 
such as nanomilling, liquid formulations, and 
amorphous solid dispersion technologies are 
given in Table 5 [36, 55, 67–78].
The chemical compatibility of the APIs with 
each other and with excipients may not be easily 
predicted from available chemical structure 
and known degradation pathways. Similarly, 
consolidation characteristics and flow properties 
of composite powder and granule blends are not 
known. Preliminary accelerated stability and 
compaction simulation design-of-experiment 
(DOE) studies are flagged for experimental 
evaluation in the feasibility assessment exercise.
There may be a need to formulate FDC 
of drugs that are designed to have different 
diffusion and dissolution kinetics in the same 
dosage form. Technology approaches used to 
achieve modified or sustained drug release can 
vary greatly and may include formulation of 
multilayer tablets having separate immediate 
release and modified-release drug layers 
either as solid granulation layers or as API 
film layer coated over an uncoated matrix 
core or over a tablet core with a polymer film 
coating [51]. Delayed-release, sustained-release 
and immediate-release multiparticulates alone 
or in combination have been designed and 
encapsulated as active containing particulates, 
or as nonpareil seeds coated with successive API 
and polymer film layers to impart different drug 
release characteristics for actives that are either 
embedded within the particulates or are spray 
coated as a film.
Pharmaceutical processing technologies 
needed to manufacture FDC with both 
immediate and sustained release performance 
are more complex and the need to conduct 
well-controlled process characterization studies 
should be documented in the feasibility 
assessment plan. Statistical experimental design 
and implementation of process monitoring 
and control strategies such as process analytic 
tools are employed and repeated at different 
scales to empirically derive the mathematical 
relationship/s between and amongst critical 
material and process parameters affecting 
product quality attributes, and to provide an 
estimate of process variability. Such DOE studies 
may eventually lead to determination of the 
design space of critical material and process 
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parameters that bounds the controlled operating 
conditions capable of consistently producing 
product meeting CQA specifications [52, 79]. In 
other aspects, a range of FDC drug loading levels 
(based on type of formulation and technology 
being employed) and required potencies can 
be used a priori to estimate overall oral dosage 
unit size, and hence, its ease of swallowing and 
patient acceptability limitations of dosing single 
or multiple units.
IP Assessment
It is important to analyze the proposed 
combination therapy against potential 
competitive therapies and FDC technologies 
that are in the pipeline, as these competitive 
technologies may appear well before the 
proposed FDC reaches the market place. 
Furthermore, a FDC may combine an 
innovator’s own therapeutic agent with a 
generically available active component which 
may still be subject to unexpired formulation 
patent or to API physical form patent such as 
a different hydrate, solvate, or polymorph. In 
these situations, the paper feasibility exercise 
should include a preliminary understanding of 
all applicable IP issues and limitations in both 
API phase and formulation design in order to 
streamline development effort.
This can be challenging particularly if generic 
API of interest has low solubility or has to be 
formulated as sustained release in the FDC. 
Such methods of composition and process are 
usually subject to rich IP protection and patent 
extensions. These factors are critically reviewed 
as they may restrict or affect the process route, 
composition, and technologies that can be 
employed to design the proposed FDC with 
its target bioperformance. In particular, a 
component of regulatory approval relies on 
establishing bioequivalent performance of 
the newly formulated FDC with respect to the 
original reference listed drug (RLD) as defined by 
FDA in its Orange Book [16].
Preclinical Safety Pharmacology 
Considerations
The need for preclinical toxicology data may 
predicate on having prior co-administration 
studies, which have demonstrated efficacy and 
safety of the proposed combination therapy 
for the target indication in clinical studies of 
patient populations. Regulatory requirements 
for conducting preclinical safety pharmacology 
studies and drug-drug pharmacokinetic 
interaction studies must be considered for novel 
combinations even if the individual components 
are known (for which no concomitant use 
data exists) and for those involving a new 
investigational drug.
Before initiating first-in-man clinical 
investigation of the combination product, it is 
necessary that the safety profiles of individual 
APIs are established. The latter includes 
conventional pharmacology and toxicology 
studies, such as genotoxicity, mutagenicity, 
and immunotoxicity. These considerations 
include establishing maximum-tolerated doses 
(or in some cases maximum feasible dose) of 
the drugs alone as well as their combination 
in GLP (good laboratory practices) acute and 
repeat dose toxicity studies in preclinical 
animal species. Maximum-tolerated single dose 
establishes preliminary safety margin related to 
proposed human dose. The no observed adverse 
effect level (NOAEL) demonstrates adequacy 
of safety margin based on projected exposures 
in humans at proposed therapeutic range and 
above milligram per kilogram doses of each 
active constituent [6, 7].
Clinical Development and Regulatory Strategy
Although several scenarios are possible 
depending on the type of FDC being developed, 
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a pilot bioavailability study in man is conducted 
early on in development to evaluate the 
bioperformance of the combination drugs 
being formulated into a single unit. The 
pharmacokinetic bioavailability study is 
designed as a crossover, open-label, single-dose 
study in a small number of healthy subjects to 
determine the comparative bioavailability of the 
FDC dosage form versus that of the individual 
active entities co-administered, on separate 
occasions, at corresponding doses. Subjects 
are randomly assigned to each of possible 
sequences with adequate washout period 
between product administrations. Furthermore, 
since the purpose of a probe pharmacokinetic 
study is to assess the probability of success of 
an eventual definitive bioequivalence study, 
wider comparative bioavailability (74–143%) 
instead of bioequivalent (80–125%) acceptance 
limits may be used. These limits bound the 
90% confidence interval of the geometric least 
square mean ratios (GMR) of both area under 
curve (AUC0-∞) (μM.hr), and Cmax (nM) of FDC 
over that of each of its corresponding active 
components. Statistics pertaining to C24°hr (nM), 
Tmax (hour) and apparent t1/2 (hour) may be 
included to inform on the shape of the systemic 
exposure profiles.
The probe pharmacokinetic study could be 
designed to include a fed arm in the same study 
subjects to determine the effect of nutrients 
on drug absorption and pharmacokinetic 
endpoints. The fed arm of the study is usually 
carried out by administering a standard meal 
(breakfast or evening meal) just prior to dosing. 
If more than one dose level is being investigated 
the fed arm may test the worst-case scenario 
by determining the effect of food/nutrients on 
pharmacokinetic parameters at only the highest 
dose. It is noted that this type of fed versus fasted 
pharmacokinetic study does not constitute a 
food effect study. A separate food effect study of 
the FDC may be warranted where the effects of 
high-fat meal versus low-fat meal on systematic 
exposure and pharmacokinetic endpoints are 
evaluated.
For combination products of previously 
approved drugs, ultimately a sufficiently 
powered definitive bioequivalence study 
is required as part of the regulatory filing 
strategy [80–82]. Drug products are considered 
therapeutically equivalent if they meet 
FDA regulatory criteria of pharmaceutical 
equivalence and bioequivalence. The definitive 
bioequivalence study uses the optimized to-be-
marketed formulation of FDC (usually at 
highest strength) versus co-administration of 
the appropriate reference drug products such 
as innovator’s own approved drugs or in the 
case of generics, the reference listed drugs at 
the strength specified in the Orange Book [16]. 
Chen et al. [83] proposed that therapeutic 
equivalence may be established by matching 
the in vivo drug delivery profile between the 
reference and the comparator drug products by 
first identifying critical variables that serve as 
in vitro markers for characterizing the desired 
drug delivery profile in vivo.
As an example, an accelerated regulatory 
filing strategy may consist of a complete 
phase 1 pharmacokinetic program, pivotal 
bioequivalent studies plus one or more clinical 
noninferiority efficacy studies (particularly 
for EU), wherein bridging to clinical safety 
and tolerability data in the original new 
drug application (NDA) submissions are 
possible. Haider et al. [84] have proposed 
a new replicate study design for adjusting 
the standard bioequivalence limits for drug 
products for which the coefficient of within 
subject variability is greater than 30%. This 
has the advantage of alleviating the need for 
large number of subjects normally required for 
traditional bioequivalence trials.
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When the FDC product contains one or 
more API formulated to possess a modified 
release profile a new NDA submission may 
generally be required, if this represents the 
first modified release formulation of the same 
previously approved immediate-release drug 
product. However, for any subsequent FDC 
in which the modified release formulation 
of an active component is considered to be 
pharmaceutically equivalent to the marketed 
controlled-release product (at the specified 
strength) aforementioned bioavailability 
and bioequivalent requirements may apply. 
Furthermore, the bioavailability studies are 
designed to establish: 1) absence of occurrence 
of any dose dumping, and 2) consistent 
pharmacokinetic performance between 
individual dosage units after both a fasted and 
fed single-dose study.
For an immediate-release/modified-release 
FDC (such as a bilayer tablet), an additional 
complicating factor may arise if no prior clinical 
data are available for the co-administration of 
the individual actives formulated as separate 
immediate release and modified release drug 
product entities. However, in one scenario, 
assuming that prior co-administration data 
does exist for immediate release versions of 
the actives, a possible resolution could be to 
provide supportive scientific literature that 
show non-inferior efficacy and similar safety of 
known immediate release and modified release 
product versions of the same API.
cONcLUsION
FDCs continue to be in the forefront of 
innovations and enhanced drug therapies for 
the treatment and management of complex 
diseases such as diabetes, hepatitis C, HIV/
AIDS, and hypertension. The rationale for the 
development of FDCs may include treatment 
of two closely related diseases, patients 
insufficiently controlled by optimally dosed 
individual mono-therapies, and substitution 
of FDC versus free combination. Other 
considerations in the development of best-in-
class commercial combination products include 
treatment paradigms in therapeutic area, 
patient compliance and impact of personalized 
medicine, shifts in market and cost drivers, 
preclinical and pharmaceutical development 
and manufacturing, competitive IP landscape, 
and clinical development and regulatory filing 
strategy. In the future, selection and screening 
of new drug combinations may be based on 
predictions from both mechanisms and targets 
of drug action as well as pharmacokinetic 
ADME properties. Combination drug therapies 
with individualized optimization are likely to 
become a major focus.
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